


MI-136

Chemical Properties

CAS No. : 1628316-74-4
 Formula: C₂₃H₂₁F₃N₆S
 Molecular Weight: 470.51
 Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Actual storage temperature shall be subject to the COA.



Biological Description

Description	MI-136 inhibits expression of androgen receptor (AR) target genes that DHT induced.
Targets(IC50)	Apoptosis,Epigenetic Reader Domain,Androgen Receptor
In vitro	MI-136, a variant of a previously described inhibitor that can specifically inhibit the menin-MLL interaction. AR positive cell lines such as VCaP, LNCaP and 22RV1 are sensitive to MI-136. Treatment with MI-136 also inhibits the expression of genes that are bound to ASH2L after AR stimulation. Treatment with MI-136 induces apoptosis of VCaP cells as evidenced by PARP (cPARP) cleavage and blocks DHT-induced cell proliferation in AR-dependent cell lines (LNCaP and VCaP). The effect of MI-136 on cell proliferation is similar to MDV-3100, a second-generation FDA-approved anti-androgen for patients with refractory prostate cancer[1].
In vivo	Treatment of VCaP tumor-bearing mice with MI-136 (40 mg/kg) leads to a modest but significant reduction in tumor volume with no effect on mouse body weight[1].
Kinase Assay	HSP90 binding, ATPase, and selectivity profiling assays: The potency of HSP90 inhibitors for HSP90 α , HSP90 β , and Grp94 is determined by AlphaScreen competition binding assays, and activity against TRAP-1 is assessed by an ATPase assay.
Cell Research	To assess the effect of MI-136 on AR signaling, VCaP cells are treated with DMSO or 5 μ M MI-136 for 48 hours. Cells are serum starved by replacing the media with DMEM containing 5% charcoal-stripped serum and MI-136 for 48 hrs. Cells are then stimulated with 10 nM DHT for 12 hrs and RNA is isolated and processed for expression microarrays. (Only for Reference)

Solubility Information

Solubility	H ₂ O: < 1 mg/mL (insoluble or slightly soluble), Ethanol: 87 mg/mL (184.91 mM),Sonication is recommended. DMSO: 150 mg/mL (318.8 mM),Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)
In vivo Formulation	10% DMSO+40% PEG300+5% Tween 80+45% Saline: 3.3 mg/mL (7.01 mM),Sonication is recommended. <i>Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one.</i>

A DRUG SCREENING EXPERT

In vivo Formulation	<i>Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.</i>
---------------------	--

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	2.1254 mL	10.6268 mL	21.2535 mL
5 mM	0.4251 mL	2.1254 mL	4.2507 mL
10 mM	0.2125 mL	1.0627 mL	2.1254 mL
50 mM	0.0425 mL	0.2125 mL	0.4251 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

Malik R, et al. Nat Med. 2015, 21(4):344-352.

Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481